Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.55 |
| ▸ | CCKBR | P32239 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392779 | 0.85 | CYP11B1 (0.43) | KCNN4KCNA3OPRK1KCNH2KMT2A | |
| Chlorotriphenylmethane SCHEMBL5351367 | 0.83 | CYP11B1 (0.39) | KCNN4KCNA3OPRK1KCNH2KMT2A | |
| SCHEMBL2388992 | 0.73 | KCNN4 (0.60) | KCNN4KCNA3OPRK1KCNH2KMT2A | |
| SCHEMBL41130 | 0.72 | KCNN4 (1.00) | KCNN4KCNA3OPRK1KCNH2KMT2A | |
| SCHEMBL29499525 | 0.72 | KCNN4 (1.00) | KCNN4KCNA3OPRK1KCNH2KMT2A | |
| SCHEMBL5479925 | 0.72 | CYP19A1 (0.66) | KCNN4KCNA3OPRK1KCNH2KMT2A | |
| SCHEMBL7789691 | 0.71 | KCNN4 (0.66) | KCNN4KCNA3OPRK1KCNH2KMT2A | |
| Clotrimazole SCHEMBL29358270 | 0.71 | CYP19A1 (1.00) | KCNN4KCNA3OPRK1KCNH2KMT2A | |
| Clotrimazole SCHEMBL1062253 | 0.71 | CYP19A1 (1.00) | KCNN4KCNA3OPRK1KCNH2KMT2A | |
| Clotrimazole SCHEMBL3850 | 0.71 | CYP19A1 (1.00) | KCNN4KCNA3OPRK1KCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS INCORPORATED | 2021-05-06 | — | — | US | claimed |
| US-20140005158-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2014-01-02 | — | — | US | claimed |
| US-20110166115-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2306830-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Corcept Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| US-20100179115-A1 | USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2010-07-15 | — | — | US | claimed |
| WO-2010002901-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| EP-2012796-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | Corcept Therapeutics, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007131041-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20020065259-A1 | Glucocorticoid blocking agents for increasing blood-brain barrier permeability | BIOPHARMA SECURED DEBT FUND II SUB, S.AR.L (LU) | 2002-05-30 | — | — | US | claimed |
| WO-2002040018-A1 | TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ALCON, INC. (CH) | 2002-05-23 | — | — | WO | claimed |
| WO-2002017930-A2 | GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD-BRAIN BARRIER PERMEABILITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-03-07 | — | — | WO | claimed |
| EP-1047410-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 2000-11-02 | — | — | EP | claimed |
| US-6051573-A | Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists | ALCON LABORATORIES, INC. (US) | 2000-04-18 | — | — | US | claimed |
| WO-1999032101-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | claimed |
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| EP-2576582-B1 | TREATMENT OF MUSCULAR DYSTROPHY | CORCEPT THERAPEUTICS INC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9782457-B2 | Flowable formulations for tissue repair and regeneration | TISSUE REPAIR COMPANY (US) | 2017-10-10 | — | — | US | disclosed |
| EP-1047410-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6051573-A | Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists | ALCON LABORATORIES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| WO-1999032101-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166115-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CRHR1, NR3C1, CRH | KCNN4 3627/4885KCNA3 3777/4885OPRK1 89/4885 |
| US-20100179115-A1 | USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CRHR2, IL2, GRIA2 | KCNN4 4370/4885KCNA3 3784/4885OPRK1 425/4885 |
| US-20140005158-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CRHR1, NR3C1, CRH | KCNN4 3627/4885KCNA3 3777/4885OPRK1 89/4885 |
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NR3C1, CRHR1, NR3C2 | KCNN4 3163/4885KCNA3 3710/4885OPRK1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.